The inhibition of thrombin is one of the important treatments of pathological blood clot formation. Variegin, isolated from the tropical bont tick, is a novel molecule exhibiting a unique 'two-modes' inhibitory property on thrombin active site (competitive before cleavage, noncompetitive after cleavage). For the better understanding of its function, we have determined the crystal structure of the human a-thrombin:synthetic-variegin complex at 2.4 Å resolution. The structure reveals a new mechanism of thrombin inhibition by disrupting the charge relay system. Based on the structure, we have designed 17 variegin variants, differing in potency, kinetics and mechanism of inhibition. The most active variant is about 70 times more potent than the FDA-approved peptidic thrombin inhibitor, hirulog-1/bivalirudin. In vivo antithrombotic effects of the variegin variants correlate well with their in vitro affinities for thrombin. Our results encourage that variegin and the variants show strong potential for the development of tunable anticoagulants.
Introduction
Serine proteinases in the blood coagulation cascade are important molecules in maintaining the integrity of hemostasis. Among them, thrombin (factor IIa) plays significant pro-and anticoagulation roles. The active site contains the classical catalytic triad -His57, Asp102 and Ser195 ( Figure 1A ). Compared to other blood coagulation serine proteinases, thrombin has a prominent active site cleft, which is deep and narrow. Two insertion loops (called the 60-loop with residues Leu59-Asn62 and the autolysisloop, residues Leu144-Gly150) form the wall of the cleft ( Figure 1A -B) [1, 2] . The thrombin active site surfaces that interact with substrate residues, at N-terminal to the scissile bond, are described as 'non-prime subsites' (S subsites). Similarly, the surfaces of the active site which are in contact with substrate residues, at C-terminal to the scissile bond, are described as 'prime subsites' (S9 subsites) ( Figure 1B ).
In addition, exosite-I is the surface near the prime subsites. The bottom of exosite-I is a deep, canyon-like cleft that extends from the prime subsites. The walls of the cleft are formed by two surface loops, Phe34-Leu39 (described as the 34-loop) and Lys70-Glu80 (the 70-loop) [2, 3] . In contrast to the apolar nature of the canyonlike cleft, the surface of exosite-I is dominated by several positivelycharged residues [4] . Exosite-II, another surface near the 'nonprime subsites', is even more basic ( Figure 1B ). The occupancy of either exosites can induce allosteric changes to the active site to enhance catalysis. The binding of Na + to the Na + binding loop (Cys220-Trp225) ( Figure 1A ) favors procoagulant functions of thrombin whereas Na + -free thrombin favors anticoagulant functions such as increased protein C activation [5] . The activity and fate of thrombin is directed by competition for its exosites and differences in distribution of its substrates and cofactors [6] .
Imbalances in blood coagulation may give rise to either loss of clotting activity, leading to hemorrhagic disorders, or unwanted clot formation, resulting in thrombosis. In particular, thrombosis causes high morbidity and mortality due to vascular occlusion and consequent myocardial infarction, stroke, pulmonary embolism, or deep-vein thrombosis. Increased atherosclerosis and thromboembolic disorders, associated with changing food habits and lifestyles, are increasing the demand for anticoagulant agents [7, 8] . Heparin and warfarin are the cornerstones of anticoagulation therapy. Unfortunately, both classes of drug have well-documented limitations such as a narrow therapeutic window and highly variable dose-response [9] . These limitations drive continual and intense efforts to develop new, efficacious and safe anticoagulants, especially for targeting specific coagulation factors [9] . Thrombin is one of the main targets for inhibition, owing to its pivotal role in coagulation. Several direct thrombin inhibitors, such as hirudin [10] , hirulog-1/bivalirudin [11] , argatroban [12] and dabigatran [13] , are currently available in the market. Among them, hirudin and hirulog-1/bivalirudin are both developed from hematophagous parasites and their success continues to inspire the search for more novel anticoagulants from these sources [14, 15] .
Recently, we described variegin, a novel, fast and tight-binding competitive inhibitor of thrombin (refers to the a form of thrombin unless otherwise stated) isolated from the tropical bont tick, Amblyomma variegatum [16] . Like hirudin/hirulog, variegin targets the thrombin catalytic site and exosite-I. However, unlike other naturally occurring thrombin inhibitors, variegin interacts with the thrombin prime subsites in addition to exosite-I [17] . Variegin has several potential advantages over hirulog-1/bivalirudin: (i) synthetic variegin (s-variegin) contains only L -amino acids, while hirulog-1/bivalirudin has a D -Phe [16] ; (ii) inhibition by variegin is about 9 times greater than hirulog-1/bivalirudin; (iii) the cleavage product of variegin (MH22) remains tightly bound to thrombin (about 400 fold stronger than cleaved hirulog-1/bivalirudin). Most importantly, MH22 potently and noncompetitively inhibits thrombin whereas cleaved hirulog-1/bivalirudin, paradoxically, activates the function of the thrombin active site [17] .
We solved the crystal structure of the thrombin:s-variegin complex at 2.4 Å resolution in order to understand the molecular interactions between thrombin and variegin. Based on the structure and data on thrombin inhibitors, a series of peptides was designed to analyse the structure-function relationships. These peptides cover a diverse spectrum of properties: potency, kinetics, mechanism of inhibition, affinities (ranging from nanomolar to picomolar values) with fast, slow, tight-binding and competitive and noncompetitive inhibition. Finally, in vivo activities of selected peptides were examined using a venous thrombosis model involving zebrafish larvae.
Methods

Synthesis, purification and mass spectrometry of peptides
Synthesis, purification and mass spectrometry analysis of all peptides were performed as described elsewhere [16] . Peptides were named with two alphabets representing the first two residues in their sequence, followed by a number representing their respective length. Position of point mutants are added after the number and italicized. Modifications to amino acids are indicated by superscript. As sulfate groups are acid labile, the peptides containing sulfotyrosine (DV24Y sulf , DV24K10RY
sulf and MH18Y sulf ) were cleaved from resins with 90% aqueous trifluoroacetic acid on ice for 5 h.
X-ray crystallography
Lyophilized recombinant human thrombin [18, 19] and svariegin were dissolved and mixed in buffer containing 50 mM HEPES (pH 7.4) and 375 mM NaCl to final concentrations of 20 mg/ml and 3 mg/ml (1:1.5 molar ratio), respectively. Crystallization was achieved using the hanging drop vapor diffusion method. Typically, 1 ml of protein solution was mixed with 1 ml of precipitant buffer (100 mM HEPES buffer pH 7.4, containing 20 to 25% PEG 8000) and equilibrated against 1 ml of the precipitant buffer at 4uC. X-ray diffraction data were collected at Beamline X29 (National Synchrotron Light Source, NY, USA). Prior to data collection, crystals were briefly soaked in a cryoprotectant solution containing the mother liquor, supplemented with 25% (v/v) glycerol. Data sets were collected using the Quantum 4 CCD detector and were processed using HKL2000 [20] . As the x 2 values for the P1 unit-cell were better than those for the C2 unitcell during data integration (around 1.0 against 3.5 and above), data were first processed under the P1 unit-cell orientation and then transformed to the C2 orientation using the transformation A = 2c+a, B = a and C = b, where a,b,c and A,B,C are the P1 and C2 unit-cell vectors, respectively.
The structure of thrombin:s-variegin complex was solved by the molecular replacement method using PHASER [21] at 2.4 Å resolution. The coordinates of the thrombin-hirulog-3 structure (PDB code: 1ABI) [22] were used as a search model. Several cycles of map fitting using program COOT [23] and refinement using program REFMAC5 [24] with one TLS [25] group per chain of thrombin led to convergence of R-values. The crystallographic and refinement statistics are listed in Table 1 . The correctness of stereochemistry of the model was verified using PROCHECK [26] and MolProbity [27] . The geometry of the thrombin molecule is comparable to that of other structures at this resolution. The peptide is relatively more flexible. The coordinates of the structure were deposited with the RCSB Protein Data Bank under the entry code 3B23. Online server PISA [28] was used to analyze the protein-peptide interface. Throughout the manuscript, the residues of thrombin and s-variegin are marked with superscripted prefixes 'T' and 'V', respectively. The chymotrypsinogen numbering system is used for numbering the thrombin residues, as first described here [29] .
Thrombin inhibition
All peptides were assayed for their abilities to inhibit thrombin amidolytic activity on chromogenic substrate S2238 (Chromo- 
Ramachandran plot
Most favored regions (%) 86.1
Additional allowed regions (%) 13.9
Generously allowed regions (%) 0
Disallowed regions (%) 0
Values in parentheses are for the last resolution shell (2.4622.40 Å ). The diffraction data were processed under the space group P1 and transformed to the space group C2 using the transformation A = 2c+a, B = a and C = b, where a,b,c and A,B,C are the P1 and C2 unit-cell vectors, respectively. doi:10.1371/journal.pone.0026367.t001
genix, Milano, Italy) as described previously [16, 17] . Values for concentration of peptide needed for 50% inhibition (IC 50 ) and inhibition constant (K i ) were calculated from data obtained were fitted using Origin software (MicroCal, Northampton, MA, USA). A detailed account for the selection and use of equations to fit the data is available in Materials and Methods S1.
Zebrafish larvae venous thrombosis model
Zebrafish and the larvae were maintained as previously described [30] . Intravenous microinjections of peptides were performed using Nanoject II (Drummond, Broomall, PA, USA) with glass injection needles. Ten nanolitres of peptides or phosphate buffered saline (PBS) were injected into 4 days post-fertilization larvae through the posterior cardinal vein. Laser ablation of larval veins were performed with a pulsed nitrogen laser light pumped through coumarin 440 dye (445 nm) (MicroPoint Laser system, Photonic Instrument, St Charles, IL, USA) at 10 pulses/s with laser intensity setting at 10. Laser ablation of each larvae was carried out 20 min after microinjection of the peptide or PBS. The laser beam was aimed at the caudal vein around five somites towards the caudal end from the anal pore and triggered for 3 s. Thrombus formation following vein injury, due to laser ablation, was monitored and the time taken for complete occlusion of the injured vein was recorded.
Results
Thrombin:s-variegin structure
The crystal structure of the thrombin:s-variegin complex was determined at 2.4 Å resolution (Table 1 and Figure 1C-D) . The electron density of the complex structure is well defined except for termini residues of chain A [ T ( 1H TFGSGE 1C ) and T Arg15]. The structure of thrombin in the complex superimposes well with other thrombin structures.
Only 17 out of the 32 residues ( V His12 to V Leu28) of s-variegin have well-defined density ( Figure 1C ). The first seven N-terminal residues do not make direct contact with thrombin [16] and svariegin is cleaved by thrombin between V Lys10 and V Met11 [16] . It is likely that the N-terminal fragment V ( 1 SDQGDVAEPK 10 ) has dissociated from thrombin after cleavage before crystallization. In contrast, the C-terminal fragment MH22 V ( 11 MHKTAPPFD-FEAIPEEYLDDES 32 ) remains bound to thrombin after cleavage [17] . The N-terminal V Met11 and the last five residues V ( 28 LDDES 32 ) of the fragment are not observed, reflecting disorder in the termini.
The C-termini of hirulog-1/-3, hirugen and hirudin have the following sequence DFEEIPEEYL(Q), with the Gln only present in hirudin. s-Variegin has an almost identical sequence V ( 19 DFEAIPEEYLDDES 32 ), with four extra residues in the Cterminus. Despite the identity, there are large differences between their conformations. The C-terminus is disordered in the hirulog-1/bivalirudin structure (PDB code: 2HGT) [4] , forming a 3 10 helix in hirulog-3 (PDB code: 1ABI) [22] and hirugen (PDB code: 1HGT [4] ) and forming a full a-helical turn in sulfo-hirudin (PDB code: 2PW8) [31] . In s-variegin, these residues remain in an extended conformation until the last observed residues ( V Leu28). The extra residues in C-terminus, although not observed in the present structure may cause the peptide to adopt the fully extended conformation ( Figure S1 ).
Interactions with thrombin catalytic residues
The active site of thrombin in the crystal structure was compared to the published data for the thrombin:hirugen structure (unoccupied active site) (Figure 2 ). Of the three catalytic residues, the most striking differences are with the Oc atom of (Figure 2A ). The newly formed hydrogen bond between T Ser195 and V His12 delocalize the electrons of T Ser195 Oc, making T Ser195 a weak nucleophile and incapable of efficiently attacking the backbone C of the substrate. This explains the observed classical non-competitive inhibition for MH22 [17] .
Interactions with prime subsites
In addition to the new hydrogen bond, the following interactions anchor s-variegin P29 to P59 residues V ( 12 HKTA 15 ) to the thrombin prime subsites ( Figure 3A (Table S1 ). The P59 V Ala is surrounded by T Gln38, T Glu39, T Arg73 and T Gln151. Thus there are extensive interactions between the variegin peptide and thrombin prime subsites.
Interactions with exosite-I
s-Variegin fits firmly into the canyon-like cleft extending from the thrombin active site to exosite-I. The walls of this hydrophobic cleft are formed by the 60-and autolysis-loops near the active site, and 34-and 70-loops at exosite-I, while many apolar residues in these loops line the bottom [2, 3] . s-Variegin is in close contact with multiple residues in exosite-I as depicted in Figure 3B . All but four residues of s-variegin ( V Phe18, V Asp19, V Ala22 and V Glu26) have their side chains buried in the interfaces with thrombin ( Figure 3A) .
Interestingly, the high identity between C-terminus of svariegin, hirulog-1/-3, hirugen and hirudin are not reflected in their respective salt bridges formation with exosite-I of thrombin. Despite the presence of multiple anionic residues in the s-variegin C-terminus and highly cationic exosite-I, only one strong salt bridge is formed ( V Glu26:
T Arg77A). This salt bridge (3.84 Å ) is not observed in hirulog-1/-3, hirugen and hirudin structures as T Arg77A adopts a different rotamer that points away from the inhibitor ( Figure 4A and S2A). In addition, a weak salt bridge is also likely between V Glu21 and T Arg75 (4.64 Å ). In hirulog-1/-3, hirugen and hirudin structures the analogous Glu makes an ion pair with T Arg75 of a 2 fold symmetry-related thrombin, although this interaction is suggested to occur within the same thrombin:inhibitor pair in solution [4, 22, 32] . In our structure, the T Arg75 side chain is rotated by 80.5u about Cb, compared to the thrombin:hirulog-3 complex ( Figure 4A and S2A) facilitating this interation. In hirulog-1/-3 and hirugen structures, an ion pair between T Arg73 and the Asp, analogous to V Asp19, can be observed. However, formation of this ion pair in the thrombin:svariegin complex is not possible as the V Asp19 side chain points in an opposite direction into solvent. This difference is most likely Figure 3C ). This s-variegin segment is in a different conformation when compared to hirulog-3/hirugen despite sequence similarity ( Figure S1 ).
Design and characterization of variegin variants
Several new variegin variants were designed based on the thrombin:s-variegin structure, as well as background information available on thrombin:inhibitor interactions. indicates flexibility and hence lack of close contacts with thrombin. As these residues are also not present in hirulogs or hirugen, two variants (EP21 and MH18) lacking the last four C-terminal residues were synthesized and characterized. IC 50 and K i values of EP21 and MH18 are essentially identical with their templates (EP25 and MH22, respectively) and indicate that the truncation of the four C-terminal residues does not alter the inhibitory activity (Table 2 ).
Previously, we have shown that the first seven N-terminal residues of variegin [ V (
)] are responsible for its fastbinding kinetics, due to a possible steering effect towards the highly basic thrombin exosite-II [16] . EP25 and EP21, in which these residues are removed, act as slow-binding inhibitor. For complete inhibition, they required 20 min of pre-incubation with thrombin. Since exosite-II is located about 10 Å away from the active site [33] , we extended EP21 by three residues at the N-terminal to include one of the two acidic residues, V Asp5, in DV24. The nonlinear progress curves of thrombin inhibition by EP21 (characteristic of slow binding inhibitors), changed to linear progress curves of inhibition by DV24 (characteristic of fast binding inhibitor) ( Figure S6 ). The IC 50 and K i values of DV24 are identical to those of s-variegin (Table 2 ). Like for s-variegin, a fast binding inhibitor, the IC 50 of DV24 increases with pre-incubation due to the cleavage by thrombin. Thus, DV24 is eight residues shorter than svariegin but retains fast-binding kinetics and potency.
(a) Optimization of thrombin:variegin interactions. As observed in the thrombin:s-variegin structure, V His12 binds to the prime subsite, with its side chain nitrogen forming hydrogen bond with T Ser195 and disrupting the charge relay system of the thrombin catalytic triad. In order to verify the significance of V His12, two variants were synthesized by replacing this residue with Ala. The two (Table 2) . Maximum inhibition by MH18H12A appears to saturate near 80% (highest concentration used is 30 mM), implying that the peptide is unable to completely inhibit thrombin. Thus, the single mutation of V His12 to Ala significantly affects the inhibitory action of the peptide, ascertaining the importance of V His12, as observed in the structure of thrombin:s-variegin complex. However, the activity is not completely abolished possibly due to other interactions in the prime subsites retained in these alanine mutants.
One striking difference between variegin and other thrombin substrates/inhibitors is the presence of Lys, instead of Arg, at P1. Typically, P1 Lys interacts with T Asp189 through a water molecule, resulting in reduced affinity and specificity [34, 35] . Therefore, using DV24 as a template sequence, the P1 residue ( V Lys10) was replaced by Arg in DV24K10R. The peptide has marginally improved IC 50 and K i values, when compared to DV24 ( Table 2) . Substitution of P1 Lys by Arg appears to accelerate the cleavage, as shown by the higher IC 50 after 20 min pre-incubation, when compared to DV24 ( Table 2) .
As in hirulogs, hirugen and hirudin, the phenyl group of Table 2) . The other variant, DV23K10R, is also less active when compared to DV24K10R, albeit to a lesser extent (Table 2) . IC 50 values of both DV23 and DV23K10R significantly increased upon pre-incubation, implies that the cleaved products no longer potently inhibits thrombin (Table 2 ). In addition, the peptide with Arg at P1 (DV23K10R) is hydrolyzed by thrombin at a faster rate than the peptide with Lys at P1 (DV23) judging from the more rapid increase of IC 50 values with pre-incubation ( Table 2) . Thus, the deletion of V Pro16 has an adverse effect on the activities of both the intact and cleaved peptides. This deletion probably compromises the interactions of P9 residues with the prime subsites, owing to their proximity to V Pro16. In hirudin, H Glu58 makes an ion-pair with T Arg77A [3, 32] . However, in variegin, this Glu is replaced by V Ala22 and its side chain is solvent exposed ( Figure 3C ). V Ala22 was replaced by Glu in variants EP25A22E and MH22A22E. The four C-terminal residues were retained in these variants to maintain the original micro-environment near the C-terminus. IC 50 and K i values of EP25A22E and MH22A22E are similar to their templates (EP25 and MH22, respectively) ( Table 2) . Thus, the replacement of V Ala22 by Glu does not enhance the activity of variegin.
Desulfation of Tyr63 in hirudin or hirugen is known to reduce their affinities to thrombin by about 10 fold [36] [37] [38] . Interestingly, the analogous residue in native variegin, V Tyr27, is not sulfated. We postulated that modification of V Tyr27 could also increase its binding affinity towards thrombin. Considering the similarity of phosphate and sulfate moieties (similar size and overall negative charge), phosphotyrosine and sulfotyrosine residues were incorporated to design new variants.
One phosphotyrosine residue was added to DV24 and DV24K10R to produce the variants DV24Y phos and DV24K10RY phos , respectively. DV24Y phos is marginally less active than DV24, whereas DV24K10RY phos has slightly improved activity ( sulf also has improved activity when compared to MH18 (Table 2) . It is very likely that the presence of sulfo-Tyr27 and the truncation of extra residues in variegin variants cause a rearrangement of the C-terminal conformation to mimic the hirugen/hirudin C-termini. Strong affinities are obtained in these variants through optimization of C-terminal interactions. Figure 5 shows the plot of Ki values of all peptides (including hirulog-1/bivalirudin). Affinity of DV24K10RY sulf for thrombin (K i = 42.066.1 pM) is ,70 fold stronger than that of hirulog-1/ bivalirudin (K i = 2.9460.12 nM). Based on the derived structureactivity relationships, we have designed a shorter (24-mer DV24K10RY sulf against 32-mer s-variegin) yet more potent thrombin inhibitor (K i of 42 pM compared to 318 pM).
In vivo antithrombotic effects of the peptides
Five inhibitors were selected as representatives to test for their antithrombotic effects in vivo using the zebrafish larvae venous thrombosis model: (1) Table 2 . Cont. N-terminal residues, has similar affinity for thrombin, but is a slow and tight-binding competitive inhibitor; (3) MH22, the cleaved product that is a fast and tight-binding, noncompetitive inhibitor; (4) DV24K10RY sulf , the most potent in vitro inhibitor that is a fast and tight-binding competitive inhibitor and (5) hirulog-1/bivalirudin, a fast, tight-binding, competitive inhibitor currently in clinical use. Hirulog-1/bivalirudin was used as a positive control.
All five peptides were injected into the zebrafish larvae circulation through the posterior (caudal) cardinal vein at a single dose (500 mM, 10 nl). The antithrombotic effects of the peptides were measured as the delay in time-to-occlusion (TTO) of the caudal vein after laser ablation ( Figure 6 ). Overall, other than EP25, the antithrombotic effects of the peptides correlated well with their affinities for thrombin. Thus, the slow-binding inhibitory mode (EP25) is not desirable for in vivo efficacy while both fast, competitive (s-variegin, DV24K10RY
sulf and hirulog-1/ bivalirudin) and fast, noncompetitive (MH22) inhibitors are effective. Our results are consistent with similar observations reported earlier about the importance of rapid thrombin inhibition for efficacious antithrombotic agents [39] .
Discussion
Variegin belongs to a unique class of thrombin inhibitors that have potential as antithrombotic agents [16, 17] . We solved the structure of thrombin:s-variegin complex at 2.4 Å resolution. Despite the use of full-length s-variegin for co-crystallization, only the density of its C-terminal fragment was observed. The cleaved fragment (equivalent to MH22) stays bound tightly to the prime subsites and exosite-I, exhibiting prolonged inhibitory action (.18 h) [17] .
Active site inhibitors of thrombin typically target the non-prime subsites, hindering the access of substrates (including the chromogenic substrate S2238 used in this study) to the catalytic residues [29, 31, 40] . The full-length variegin also acts in a similar way and competitively inhibits the thrombin active site [16] . The present thrombin:s-variegin structure reveals two exciting features: (1) the novel mechanism of thrombin inhibition through disruption of the charge relay system, and (2) the binding with thrombin prime subsites. The cleaved product (MH22) still retains inhibition through this novel mechanism, as observed in the structure. The lack of overlaps in MH22 and S2238 binding sites (non-prime and S19 subsites), demonstrates the feasibility of simultaneous binding of S2238 and MH22 to thrombin with no changes in affinities of either ( Figure S20 ). The binding of substrate (S2238) to the thrombin active site becomes non-productive due to the disruption of the charge relay system by MH22 (Figure 2 ). We also speculate that the binding of variegin/MH22 to the prime subsites induces minor structural changes that may interfere with the entry of S2238 or exit of products from the active site without affecting the strength of substrate binding. Thus the structure explains the classical noncompetitive inhibition by MH22.
The interaction between the variegin and thrombin prime subsites is equally interesting. The S9 subsites' interactions between the inhibitors and protease are important for binding [41] . A systematic probing of thrombin S9 subsites with 'methyl scan' also has demonstrated the potential for targeting prime subsites in the design of inhibitors [42] . However, unlike variegin, other naturally occurring thrombin inhibitors, including hirudin [31] , rhodniin [43] , ornithodorin [44] and boophilin [45] , are not inserted into the canyon-like cleft (the prime subsites) connecting the active site and exosite-I. Similarly, the previous structures of thrombin, in complex with other macromolecular substrates [46] [47] [48] [49] [50] , typically lack complete details in the interactions within this region. Thus, when compared to the non-prime subsites, understanding of the binding preferences for the thrombin prime subsites (especially S29 and beyond) is much less complete [1] . Recently, the structure of a PAR1 fragment in complex with an inactive thrombin mutant T Ser195A was published [51] . This structure provided new details on the interaction within the prime subsites. However, there is considerable disorderliness in the PAR1 molecule binding to this region. As a result, it was suggested that the prime subsites binding segment of PAR1 snaps away from thrombin upon cleavage [51] . In the case of substrates, such a mechanism is probably advantageous to ensure a faster turnover. However, inhibitors are developed to bind to thrombin as tight and long as possible. In this specific case, variegin has evolved to bind to the thrombin prime subsites and thus the structure of the thrombin:s-variegin complex provides a unique opportunity to understand the interaction of this inhibitor with the thrombin prime subsites which is of extreme importance to the design of more effective inhibitors.
In hirulog-1/bivalirudin, the glycyl linkers connect the active site and exosite-I binding moieties without displaying specific interactions with the thrombin prime subsites. As a result, this segment is disordered in the crystal structure [4] and the activity is rapidly lost after cleavage by thrombin [17, 52] . When anchored by a non-hydrolyzable active site binding moiety and an exosite-I binding segment, the non-specific linker is forced to fit into the canyon-like cleft in the prime subsites, as seen in hirulog-3 [22] and P498 [40] . In these cases, the S9 subsite interactions are suboptimal due to the lack of specific side chain interactions. As a result, extensive and lengthy optimizations, through synthetic chemistry using multiple and unnatural amino acids, were necessary to produce inhibitors with enhanced binding to the prime subsites [42, 53, 54] . In contrast, tight binding of s-variegin to the prime subsites is achieved through specific interactions involving the side chains of natural amino acids. Thus the thrombin-variegin complex provides important and detailed structural information for inhibition of the thrombin prime subsites. This structural observation for the prime subsites binding in variegin is also consistent with the structure-function data presented here and elsewhere [16, 17] . The firm insertion of variegin peptides into the cleft in an extended conformation is probably the simplest structure needed to achieve strongest and instantaneous binding to the thrombin catalytic pocket, prime subsites and exosite-I. This 'minimalistic' approach in nature (ticks) confers an advantage of minimum energy expenditure (protein synthesis) for maximum outcome (potent inhibition of coagulation enzymes to facilitate blood-feeding).
Based on the thrombin:s-variegin structure and other available information, we performed targeted structure-function relationship studies on variegin. Substitution of P1 Lys by Arg is reported to increase affinity for thrombin by ,10 fold through a better fit to the S1 subsite [2, 35] . However, our results show that the improvement in affinity by this substitution varies. In DV24, DV24Y
sulf and DV24Y phos , the effects of substitution are less than 2 fold. It is likely that the extensive interactions between the svariegin P9 residues and thrombin S9 subsite compensate for the loose fitting of P1 Lys. In contrast, DV23/DV23K10R-thrombin interactions around the prime subsites are likely to be disturbed due to the deletion of Pro16 (DV23 K i is ,7 fold higher than DV24). In this situation, P1 Arg facilitates stronger binding of the V (   5   DVAEPR 10 ) sequence to the active site compared to P1 Lys, which is reflected by the higher gain in affinity (,4 fold decrease in K i ). These results further support the importance of prime subsite interactions.
We have also shown that addition of three residues at the Nterminus of the slow-binding inhibitor EP21 changes it to a fastbinding inhibitor. Thus, the prime subsites anchoring effect (discussed above) mainly drives affinity for the thrombin active site, while the N-terminal steering effect is needed for proper preorientation of this segment. Hence, the P1 to P3 residues of svariegin are inserted rapidly into the thrombin active site, assisted by prime subsites targeting and the N-terminal negative charge. Once in the acidic S1 pocket, P1 Lys/Arg interacts with T Asp189 with only a minimal overall loss of binding strength. This suggests a less stringent requirement for the P1 residue that can be exploited for the design of new specific thrombin inhibitors. In addition to the prime subsite interaction, V His12 draws T Ser192 out of position and affects the geometry of the crucial catalytic residue as well as interfering in the charge relay system. The result is decreased catalytic efficiency. Such a design may be exploited in the development of inhibitors for other serine proteases.
The new variegin variants cover a big range of potency, speed of onset and kinetic parameters, showing the potential to 'tune' variegin to provide different therapeutic properties. The unique ability of variegin to potently inhibit thrombin (initially competitive, subsequently noncompetitive) for a long duration represents a new approach to anticoagulation when compared to other direct thrombin inhibitors on the market. Variegin and some of its variants inhibit thrombin potently with low K i (between 0.04 to 0.4 nM). Their affinities for thrombin are stronger than hirulog-1/ bivalirudin (K i = 2.3 nM) [55] , argatroban (K i = 3.2 nM) [56] and dabigatran (K i = 4.5 nM) [57] but weaker than hirudin (K i = 0.2 pM) [36] . While weaker affinities may translate to lower efficacy and increased probability of side effects, the almost irreversible binding of hirudin to thrombin (K i = 0.2 pM) may be responsible for an increased risk of major bleeding when compared to unfractionated heparin [58] . Thus, in terms of affinity for thrombin, variegin may represent a good balance between potency and safety. The prolonged action of variegin might also allow single dose administration instead of continuous infusion (as in the case of hirulog-1/bivalirudin) [11] especially in short procedures such as percutaneous coronary intervention. We also have preliminary data showing the possibility of using protamine as antidote for variegin. Overall, variegin (with its variants) represents a fine balance between hirudin and hirulog-1/bivalirudin for most of their properties (K i , size, duration of action etc.). At this point, the strong in vivo antithrombotic effects support the continual development of variegin and its variants as potential and improved anticoagulants. 65 nM) inhibited by EP25 (0.1 nM, 0.3 nM, 1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1000 nM, 3000 nM) in S2238 (100 mM) showed a left shift with increased pre-incubation time due to slow binding. IC 50 Figure S20 Noncompetitive inhibition of thrombin by MH22. s-Variegin binds to both the non-prime and prime subsites of thrombin active site and is cleaved between Lys-Met. After cleavage, the fragment C-terminal to the scissile bond (MH22) noncompetitively inhibits thrombin. The chromogenic substrate S2238 binds mainly to the non-prime subsites and is cleaved between Arg and para-nitroaniline (pNA). The overlaps between s-variegin and S2238 binding sites resulted in the observed competitive inhibition. In contrast, the noncompetitive inhibition observed for MH22 showed the lack of overlaps between MH22 and S2238 even in the S19 subsite (red box). Indeed, no density was observed for P19 Met in the present structure, most likely reflects the lack of contact with thrombin and hence leaves a free S19 site for the binding of pNA moiety when MH22 is bound to thrombin. (TIF) Table S1 A list of possible direct hydrogen bonds between svariegin and thrombin calculated based on the online server PISA [28] .
Supporting Information
(TIF)
Materials and Methods S1 A detailed account for the selection and use of equations to fit the data of thrombin inhibitions is available in Materials and Methods S1. (DOC)
